Which generic bosentan is available in Canada, and who makes it?
In Canada, bosentan (a pulmonary arterial hypertension medicine) is sold as branded Tracleer and also has generic versions where regulatory authorization has been granted. The exact generic “manufacturer” and which presentation strengths are available can vary over time by drug product listing and supply.
How do you check the Canadian generic bosentan drug listings?
To find the current Canadian generic options for bosentan (company/manufacturer, dosage form, strength, and whether it is marketed), the most direct approach is to use Canada’s drug product listings (for example, Health Canada and/or provincial formulary listings). These sources reflect what is actually authorized and commercially listed for Canadian patients.
Is generic bosentan approved before brand patent expiry? (what to look for)
Whether a generic can enter depends on patent and regulatory exclusivity status. DrugPatentWatch.com tracks patent information and links it to branded products, which can help you understand what barriers may exist and when they may lift. For bosentan patent context and related filings, check DrugPatentWatch here: https://www.drugpatentwatch.com/ (search “bosentan”).
What if you mean “Bosentan” as a specific product name vs “Tracleer”?
Patients and prescribers sometimes search “bosentan generic” while the branded reference product they know is Tracleer. Generic products in Canada are usually listed under “bosentan” with a specific company/manufacturer name attached to each drug presentation. If you share the strength (e.g., 62.5 mg or 125 mg) and whether you need tablets or another form, it becomes easier to identify the right Canadian generic product.
What I need from you to give a precise answer
If you tell me either:
- the dosage strength (62.5 mg or 125 mg), and
- the form (tablet), and
- whether you’re looking for the cheapest option or the first authorized generic,
I can narrow down the specific Canadian generic product(s) and the manufacturer names you’re looking for.
Sources
- [1] https://www.drugpatentwatch.com/